Efficacy of atypical antipsychotics in schizophrenia patients: effects of 5-HTR SNPs.

IF 3.6 3区医学 Q1 PSYCHIATRY

Annals of General Psychiatry Pub Date : 2025-02-18 DOI:10.1186/s12991-025-00547-z

Keying Liu, Bide Zhang, Zhoufangyuan Chen, Fukun Chen, Zexu Li, Yunzhi Gao, Yuechao Zhao, Yihao Liu, Yanlong Wang

{"title":"Efficacy of atypical antipsychotics in schizophrenia patients: effects of 5-HTR SNPs.","authors":"Keying Liu, Bide Zhang, Zhoufangyuan Chen, Fukun Chen, Zexu Li, Yunzhi Gao, Yuechao Zhao, Yihao Liu, Yanlong Wang","doi":"10.1186/s12991-025-00547-z","DOIUrl":null,"url":null,"abstract":"<p><p>The 5-hydroxytryptamine receptor (5-HTR) is a key protein responsible for the effects of 5-hydroxytryptamine (5-HT) and an important target for many antipsychotics. 5-HTR has a high degree of genetic polymorphism, and atypical antipsychotics are 5-HTR antagonists widely used in treating schizophrenia. With the increasing development of medical technology, antipsychotics are being updated rapidly, and their efficacy and safety are being optimised. However, owing to the complexity of patients' genetic polymorphisms and psychiatric disorders, there are still individual differences in clinical efficacy. This article reviews the typing of 5-HTR, a common target of clinical atypical antipsychotics, and the effects of 5-HTR gene single nucleotide polymorphisms (SNPs) on the efficacy of atypical antipsychotics. Specific genotypes of six types of 5-HTR genes are associated with differential responses to atypical antipsychotics, which may help guide the development of individualized clinical treatments for patients with schizophrenia.</p>","PeriodicalId":7942,"journal":{"name":"Annals of General Psychiatry","volume":"24 1","pages":"10"},"PeriodicalIF":3.6000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837449/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of General Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12991-025-00547-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

The 5-hydroxytryptamine receptor (5-HTR) is a key protein responsible for the effects of 5-hydroxytryptamine (5-HT) and an important target for many antipsychotics. 5-HTR has a high degree of genetic polymorphism, and atypical antipsychotics are 5-HTR antagonists widely used in treating schizophrenia. With the increasing development of medical technology, antipsychotics are being updated rapidly, and their efficacy and safety are being optimised. However, owing to the complexity of patients' genetic polymorphisms and psychiatric disorders, there are still individual differences in clinical efficacy. This article reviews the typing of 5-HTR, a common target of clinical atypical antipsychotics, and the effects of 5-HTR gene single nucleotide polymorphisms (SNPs) on the efficacy of atypical antipsychotics. Specific genotypes of six types of 5-HTR genes are associated with differential responses to atypical antipsychotics, which may help guide the development of individualized clinical treatments for patients with schizophrenia.

查看原文本刊更多论文

非典型抗精神病药物对精神分裂症患者的疗效：5-HTR snp的影响。

5-羟色胺受体（5-HTR）是负责5-羟色胺（5-HT）作用的关键蛋白，也是许多抗精神病药物的重要靶点。5-HTR具有高度的遗传多态性，非典型抗精神病药物是广泛用于治疗精神分裂症的5-HTR拮抗剂。随着医疗技术的不断发展，抗精神病药物也在不断更新换代，其疗效和安全性也在不断优化。但由于患者遗传多态性和精神障碍的复杂性，临床疗效仍存在个体差异。本文综述了临床非典型抗精神病药物常见靶点5-HTR的分型，以及5-HTR基因单核苷酸多态性（snp）对非典型抗精神病药物疗效的影响。6种5-HTR基因的特定基因型与非典型抗精神病药物的差异反应相关，这可能有助于指导精神分裂症患者个性化临床治疗的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of General Psychiatry PSYCHIATRY-

CiteScore

6.60

自引率

2.70%

发文量

审稿时长

>12 weeks

期刊介绍： Annals of General Psychiatry considers manuscripts on all aspects of psychiatry, including neuroscience and psychological medicine. Both basic and clinical neuroscience contributions are encouraged. Annals of General Psychiatry emphasizes a biopsychosocial approach to illness and health and strongly supports and follows the principles of evidence-based medicine. As an open access journal, Annals of General Psychiatry facilitates the worldwide distribution of high quality psychiatry and mental health research. The journal considers submissions on a wide range of topics including, but not limited to, psychopharmacology, forensic psychiatry, psychotic disorders, psychiatric genetics, and mood and anxiety disorders.